ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,405Medicare Part D Prescriptions Filled, Including Refills

Rank: 20 out of 300

$518K Total Retail Price of All Prescriptions

Rank: 33 out of 300

340 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 340 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

20% of this provider’s 340 patients filled at least one prescription for a schedule three drug, compared to an average of 21%.

Risky Drugs to Seniors

2% of this provider’s 6,541 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 5%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $75 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
OMEPRAZOLE 378 253 1 2
SIMVASTATIN 338 283 2 3
LISINOPRIL 315 243 3 7
HYDROCODONE-ACETAMINOPHEN 296 201 S3 4 1
LEVOTHYROXINE SODIUM 268 178 5 12
AMLODIPINE BESYLATE 221 195 6 4
GABAPENTIN 200 113 7 6
METFORMIN HCL 197 123 8 24
FUROSEMIDE 193 154 9 5
CARVEDILOL 172 151 10 8
PRAVASTATIN SODIUM 156 58 11 17
POTASSIUM CHLORIDE 154 120 12 20
PREDNISONE 148 88 13 50
SERTRALINE HCL 138 52 14 40
ATORVASTATIN CALCIUM 111 91 15 13
NEXIUM 110 74 16 44
PROAIR HFA 110 55 16 80
LOSARTAN POTASSIUM 108 99 18 29
RANITIDINE HCL 107 55 19 63
DONEPEZIL HCL 103 99 20 33
LISINOPRIL-HYDROCHLOROTHIAZIDE 103 70 20 47
SINGULAIR 101 44 22 115
DOXYCYCLINE HYCLATE 95 60 23 97
TIZANIDINE HCL 94 52 24 10
WARFARIN SODIUM 93 81 25 23
CITALOPRAM HBR 90 59 26 46
CYMBALTA 89 41 27 54
TAMSULOSIN HCL 88 85 28 9
CLOPIDOGREL 86 82 29 18
HYDROCHLOROTHIAZIDE 85 45 30 21
ZOLPIDEM TARTRATE 85 51 30 16
ATENOLOL 83 59 32 27
CLONIDINE HCL 82 63 33 39
FENOFIBRATE 79 43 34 73
TRAMADOL HCL 77 61 35 11
DIGOXIN 68 56 36 36
SPIRIVA 67 34 37 53
AZITHROMYCIN 66 45 38 71
METOPROLOL TARTRATE 65 54 39 26
SPIRONOLACTONE 64 47 40 69
CYCLOBENZAPRINE HCL 64 21 R 40 35
ADVAIR DISKUS 63 40 42 75
FLUTICASONE PROPIONATE 63 51 42 34
PLAVIX 63 57 42 32
TRAZODONE HCL 57 40 45 51
VENTOLIN HFA 57 36 45 125
LYRICA 54 23 47 31
METOPROLOL SUCCINATE 53 48 48 15
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.